- Trials with a EudraCT protocol (31)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
31 result(s) found for: Cell Signalling.
Displaying page 1 of 2.
EudraCT Number: 2010-018776-24 | Sponsor Protocol Number: HIPPoS | Start Date*: 2010-11-21 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Proof of mechanism study of an oral hedgehog inhibitor (GDC-0449) in patients with resectable pancreatic ductal adenocarcinoma in the pre-operative window period. | |||||||||||||
Medical condition: Pancreatic ductal adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023479-24 | Sponsor Protocol Number: 01/2010 | Start Date*: 2011-02-03 | |||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | |||||||||||||
Full Title: Effect of Interleukin-1 receptor antagonist on insulin sensitivity in subjects with type 1 diabetes mellitus. | |||||||||||||
Medical condition: diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004655-31 | Sponsor Protocol Number: 1143-SCCHN-202 | Start Date*: 2015-03-25 | |||||||||||
Sponsor Name:Debiopharm International S.A. | |||||||||||||
Full Title: Preoperative window-of-opportunity (WoO) study of Debio 1143 with or without cisplatin (CDDP) in patients with resectable squamous cell carcinoma of the head and neck. | |||||||||||||
Medical condition: Squamous cell carcinoma of the head and neck | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001058-16 | Sponsor Protocol Number: NLG-LBC-07 | Start Date*: 2017-02-15 | |||||||||||
Sponsor Name:Nordic Lymphoma Group | |||||||||||||
Full Title: A Phase II Trial of Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma. | |||||||||||||
Medical condition: Relapsed/refractory diffuse large B-cell lymphoma, including transformed low grade lymphoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012714-49 | Sponsor Protocol Number: CHUBX 2009/04 | Start Date*: 2009-11-24 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: Pilot study of Lapatinib (Tyverb®) in néoadjuvant treatment for patients with locally bladder carcinoma before cystectomy | |||||||||||||
Medical condition: Bladder carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004269-14 | Sponsor Protocol Number: HP002-001 | Start Date*: 2018-05-07 |
Sponsor Name:Hamlet Pharma AB | ||
Full Title: A Randomized Placebo controlled Phase I/II Study Evaluating the Safety and Efficacy of Alpha1H in adult patients with non-muscle invasive bladder cancer awaiting transurethral surgery | ||
Medical condition: Non-muscle invasive bladder cancer awaiting transurethral surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005425-30 | Sponsor Protocol Number: AURA-6202-011 | Start Date*: 2008-04-17 | |||||||||||
Sponsor Name:Nerviano Medical Sciences S.r.l. | |||||||||||||
Full Title: An Exploratory Phase II Study of PHA-739358 in Patients with Multiple Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression | |||||||||||||
Medical condition: Multiple Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005096-42 | Sponsor Protocol Number: BO18279 | Start Date*: 2005-06-24 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: A phase II marker identification trial for Tarceva in second line NSCLC patients | ||
Medical condition: Advanced (stage IIIb and IV) non small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) GB (Completed) EE (Completed) DE (Completed) IT (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-011882-10 | Sponsor Protocol Number: GETUG-AFU 19/0901 | Start Date*: 2010-02-26 | |||||||||||
Sponsor Name:FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer) | |||||||||||||
Full Title: Intensified methotrexate, vinblastine, doxorubicin and cisplatin (I-MVAC) with or without panitumumab as first-line treatment of advanced urothelial carcinoma in patients without H-Ras nor K-Ras mu... | |||||||||||||
Medical condition: Advanced urothelial carcinoma in patients without H-Ras nor K-Ras mutations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001653-27 | Sponsor Protocol Number: UC_0105-1305_/_IFCT_1301 | Start Date*: 2014-07-24 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic non small cell lung cancer | |||||||||||||
Medical condition: Patients with metastatic non small cell lung cancer (NSCLC) in 1st line chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000900-41 | Sponsor Protocol Number: WB28850 | Start Date*: 2013-05-10 |
Sponsor Name:F. Hoffmann-La Roche, Ltd. | ||
Full Title: A STUDY TO MEASURE SERUM PERIOSTIN, ASTHMA-RELATED BIOMARKERS AND RESPONSE TO PREDNISOLONE IN ADULT AND ADOLESCENT PATIENTS WITH SEVERE ORAL CORTICOSTEROID-DEPENDENT ASTHMA | ||
Medical condition: Severe corticosteroid-dependent asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003928-31 | Sponsor Protocol Number: GN15ON133 | Start Date*: 2016-09-22 | ||||||||||||||||||||||||||
Sponsor Name:NHS Greater Glasgow and Clyde [...] | ||||||||||||||||||||||||||||
Full Title: A Phase I/IIA Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients with Advanced Solid Malignancies | ||||||||||||||||||||||||||||
Medical condition: Advanced, incurable cancer with no remaining standard-of-care treatment options that are suitable. Or where pembrolizumab is a licensed treatment option at that line of therapy. In Phase I, this ma... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001491-35 | Sponsor Protocol Number: CB103-C-101 | Start Date*: 2017-08-11 | ||||||||||||||||
Sponsor Name:Cellestia Biotech AG | ||||||||||||||||||
Full Title: A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adu... | ||||||||||||||||||
Medical condition: advanced or metastatic solid tumours and haematological malignancies | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) NL (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000179-38 | Sponsor Protocol Number: ESR-21-21168 | Start Date*: 2022-04-28 | |||||||||||
Sponsor Name:Bispebjerg Hospital | |||||||||||||
Full Title: Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomized double-blind, placebo-controlled trial of tezepelumab | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004677-20 | Sponsor Protocol Number: Gemtax IV | Start Date*: 2006-03-17 |
Sponsor Name:University of Heidelberg, Klinikum Mannheim, Dep Surgery/Thoracical Oncology | ||
Full Title: Randomised Phase II/III Study on Sectional Single Agent Gemcitabine and Docetaxel Versus Carboplatine / Gemcitabine Doublet Therapy, both combined Cetuximab in the Treatment of Advanced NSCLC (Stag... | ||
Medical condition: Lung cancer remains the leading cause of cancer-related death in men and has increased its incidence in women over the past decades (protocol page 9). Data from both meta-analysis and clinical tria... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) LT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000154-19 | Sponsor Protocol Number: UC-0105/1701 | Start Date*: 2017-07-19 |
Sponsor Name:UNICANCER | ||
Full Title: A phase II randomized trial comparing alpelisib and fulvestrant versus chemotherapy as maintenance therapy in patients with PIK3CA mutated advanced breast cancer | ||
Medical condition: PIK3CA mutated, HR+/Her2- metastatic breast cancer who do not present progressive disease after 6-8 cycles of 1st or second line chemotherapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003641-15 | Sponsor Protocol Number: 2625 | Start Date*: 2013-07-04 |
Sponsor Name:North Bristol NHS Trust | ||
Full Title: Reducing pathology in Alzheimer’s Disease through Angiotensin taRgeting. The RADAR Trial. A phase II, two arm, double-blind, placebo-controlled, randomised trial to evaluate the effect of losartan ... | ||
Medical condition: Alzheimer's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002109-73 | Sponsor Protocol Number: NiCCC2013 | Start Date*: 2013-11-14 | ||||||||||||||||
Sponsor Name:Greater Glasgow Health Board | ||||||||||||||||||
Full Title: A Randomised Phase II Study of Nintedanib (BIBF1120) Compared to Chemotherapy in Patients with Recurrent Clear Cell Carcinoma of the Ovary or Endometrium | ||||||||||||||||||
Medical condition: Recurrent clear cell carcinoma of the ovary or endometrium | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: GB (Completed) FR (Completed) NL (Completed) DK (Prematurely Ended) FI (Prematurely Ended) NO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002613-31 | Sponsor Protocol Number: 009896QM | Start Date*: 2015-04-27 |
Sponsor Name:Queen Mary University of London | ||
Full Title: A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers. | ||
Medical condition: Triple-Negative Breast Cancer Non-squamous Small Cell Lung Cancer Squamous Cell Lung Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2006-006079-19 | Sponsor Protocol Number: RE05 | Start Date*: 2007-04-02 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse | |||||||||||||
Medical condition: Renal Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DK (Completed) BE (Completed) FR (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.